The FDA’s IDE approval allows Presidio to initiate a randomized, controlled trial in the United States and Australia to evaluate the safety and efficacy of its ULF neuromodulation technology
HeartBeam's innovative 3D ECG technology revolutionizes cardiac monitoring, enhancing remote patient care and enabling timely interventions for heart conditions.
RenovoCath is designed to deliver diagnostic and therapeutic agents directly to targeted tissues, offering a localized approach to treatment that can minimize systemic exposure.